Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray

2005 ◽  
Vol 95 (2) ◽  
pp. 403-418 ◽  
Author(s):  
Jude E. Onyia ◽  
Leah M. Helvering ◽  
Lawrence Gelbert ◽  
Tao Wei ◽  
Shuguang Huang ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Dna Microarray ◽  
Molecular Profile ◽  
Treatment Regimens ◽  
Anabolic Treatment ◽  
Rat Bone

Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats

2017 ◽  
Vol 7 (4) ◽  
pp. 482-496 ◽  
Author(s):  
Yang Yang ◽  
Ali Aghazadeh-Habashi ◽  
Arash Panahifar ◽  
Yuchin Wu ◽  
Krishna H. Bhandari ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Bone Targeting ◽  
Anabolic Treatment

scholarly journals The use of PTH in the treatment of osteoporosis

2010 ◽  
Vol 54 (2) ◽  
pp. 213-219 ◽  
Author(s):  
Victória Z. Cochenski Borba ◽  
Nádila Cecyn Pietszkowski Mañas
Keyword(s):  
Parathyroid Hormone ◽  
Bone Density ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Biochemical Markers ◽  
Osteoporosis Treatment ◽  
Antiresorptive Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Anabolic Treatment

Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.

Effect of Magnesium Deficiency on Rat Bone and Kidney Sensitivity to Parathyroid Hormone

1980 ◽  
Vol 110 (8) ◽  
pp. 1610-1617 ◽  
Author(s):  
Richard M. Forbes ◽  
Helen M. Parker
Keyword(s):  
Parathyroid Hormone ◽  
Magnesium Deficiency ◽  
Rat Bone

scholarly journals Recombinant human parathyroid hormone in the therapy of hypoparathyroidism

2017 ◽  
Vol 89 (10) ◽  
pp. 80-86 ◽  
Author(s):  
A K Eremkina ◽  
N G Mokrysheva ◽  
E V Kovaleva ◽  
Yu A Krupinova
Keyword(s):  
Parathyroid Hormone ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Normal Serum ◽  
Biologically Active ◽  
Vitamin D Metabolites ◽  
Treatment Regimens ◽  
Normal Serum Calcium ◽  
Pathogenetic Therapy ◽  
Dosing Regimens

Hypoparathyroidism is an endocrine disease that results from deficiency or complete absence of parathyroid hormone (PTH), a biologically active 84-amino acid polypeptide. Standard therapy for chronic hypoparathyroidism includes oral calcium salts and active vitamin D metabolites and is aimed at maintaining a balance between optimal near-normal serum calcium concentration and normocalcuria. Traditional treatment regimens not always lead to the compensation for calcium and phosphorus metabolism. Until recently, hypoparathyroidism is the only endocrine disorder that has not been treated with the recombinant hormone. To date, two recombinant PTH forms have been synthesized, which can be used as pathogenetic therapy for hypoparathyroidism. This review is dedicated to replacement therapy for hypoparathyroidism, by using both the full-length PTH molecule (1—84) and its shorter, but fully active, PTH form (1—34). This review considers stages in the developmental of hormone replacement therapy for hypoparathyroidism, discusses the most rational dosing regimens, and compares their efficacy and safety, as well as prospects for the development of this area.

Sign in / Sign up

Export Citation Format

Share Document